NCI Funds 24 DNA Microarray Laboratories Nationwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

BETHESDA, Md-Twenty-four cancer research centers in the United States will receive a total of $4.1 million from the National Cancer Institute to purchase the necessary equipment to establish DNA microarray facilities. The new and technically challenging research tool enables scientists to assess expression levels of a large subset of the human genes in a cell or tissue.

BETHESDA, Md—Twenty-four cancer research centers in the United States will receive a total of $4.1 million from the National Cancer Institute to purchase the necessary equipment to establish DNA microarray facilities. The new and technically challenging research tool enables scientists to assess expression levels of a large subset of the human genes in a cell or tissue.

The NCI intends for the DNA microarray laboratories to provide technical support to cancer researchers and to make the technology widely available so that it is rapidly applied to investigating a broad range of critical problems in cancer research.

Articles in this issue
Anti-VEGF MoAb Promising in Phase II Renal Cancer Study
Government Lawsuit Seeks Billions From Tobacco Industry
NCI Plans a Large Phase III Trial of Lymphoma Vaccine
NCCN Database Expanding to Include Cancer Pain Outcomes
Fewer Blacks Than Whites Receive Surgery for Early Stage Lung Cancer
NSABP Trial Examines Surgery’s Role in Breast Cancer
Congressional Spouses Honor Three for Cancer Prevention
Prophylactic Tamoxifen Debated at ECCO
Survival Advantage for Simultaneous Goserelin and RT
NCCR Honors Seven Members of Congress as ‘Champions’
Even With Coverage, Patients Avoid Clinical Trials
MVAC Still the ‘Best Treatment’ for Advanced Bladder Cancer Patients
AstraZeneca Offers CHOICES Prostate Education Program
Candlelight Vigil Rekindles Enthusiasm of ‘The March’
QUASAR Shows No Benefit for Levamisole in Colorectal Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Related Content
Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress.

Pertuzumab Combo Reduces Risk of Death in HER2+ Early-Stage Breast Cancer

Roman Fabbricatore
May 13th 2025
Article

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
Article
Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.